ArticleEpilepsia2026
Effects of fenfluramine and sigma-1-dependent pharmacological and genetic modulation in a mouse kindling model.
Article in Epilepsia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sigma-1 Expression in Chronic Mouse Models of Temporal Lobe Epilepsy.Molecular neurobiology · 2026Article
- Effects of fenfluramine and sigma-1-dependent pharmacological and genetic modulation in a mouse kindling model.Epilepsia · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveSigma-1 is a chaperone protein that serves as a key homeostatic regulator, implicated in neuronal excitability and seizure control. Positive allosteric modulators offer a use-dependent means to enhance Sigma-1 activity, potentially with favorable tolerability compared to direct agonists. This study examined the role of sigma-1 in ictogenesis, seizure spread, and termination, and evaluated whether sigma-1 targeting could modify progression in the amygdala kindling model.
methodsUsing the mouse amygdala kindling paradigm, we assessed the effects of subchronic administration of the sigma-1 positive allosteric modulator E1R and of the antiseizure medication fenfluramine on seizure thresholds, severity, duration, and progression of kindling. Tolerability, behavioral outcomes, and potential disease-modifying effects were evaluated. Additional experiments investigated the influence of sigma-1 antagonism (NE-100) and genetic sigma-1 deficiency on E1R efficacy and seizure development.
resultsE1R delayed kindling acquisition, increased seizure thresholds in both naïve and kindled animals, and reduced seizure duration without evidence of tolerance or significant adverse effects. Subchronic E1R exposure slowed or prevented progression to generalized seizures, although effects did not persist after drug withdrawal. Sigma-1 deficiency prolonged seizure duration, supporting a role in the termination of endogenous seizures. High-dose NE-100 partially antagonized E1R effects, whereas genetic deficiency did not, possibly due to compensatory mechanisms. Fenfluramine did not affect kindling progression in this model. SIGNIFICANCE: Positive allosteric modulation of sigma-1 attenuates ictogenesis and seizure severity and appears to contribute to endogenous seizure-termination mechanisms. Although E1R influences seizure generation in response to repeated stimulation, it does not produce sustained disease-modifying effects after discontinuation. These findings support a functional role of sigma-1 positive allosteric modulators as promising candidates for seizure management in the model used. The absence of persistent effects after withdrawal argues against disease modification under the current conditions and warrants further investigation in chronic epilepsy models evaluating long-term therapeutic, disease-modifying, or preventive potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.